Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1364-8535
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated) ; volume:9 ; number:5 ; day:27 ; month:7 ; year:2005 ; pages:1-6 ; date:10.2005
Critical care ; 9, Heft 5 (27.7.2005), 1-6, 10.2005
- Urheber
-
Levy, Howard
- Beteiligte Personen und Organisationen
-
Laterre, Pierre-François
Bates, Becky
Qualy, Rebecca L.
SpringerLink (Online service)
- DOI
-
10.1186/cc3778
- URN
-
urn:nbn:de:1111-201608087578
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Levy, Howard
- Laterre, Pierre-François
- Bates, Becky
- Qualy, Rebecca L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Physiological-dose steroid therapy in sepsis [ISRCTN36253388]
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Physiological-dose steroid therapy in sepsis [ISRCTN36253388]
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Physiological-dose steroid therapy in sepsis [ISRCTN36253388]
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C